Evidence map›Paper›PMID 30931486›Full record

ArticleMetabolic brain disease2019

Selective inhibition of intestinal 5-HT improves neurobehavioral abnormalities caused by high-fat diet mice.

Qi Pan, Qiongzhen Liu, Renling Wan, Praveen Kumar Kalavagunta, Li Liu, Wenting Lv, Tong Qiao, Jing Shang, Huali Wu

Abstract read
PubMed Publisher
In one paragraph

Article in Metabolic brain disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Molecules (Basel, Switzerland) · 2024
    Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Protein, amino acids and obesity treatment.Reviews in endocrine & metabolic disorders · 2020
    Review
  13. Review
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Qi PanState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China.
Qiongzhen LiuState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China.
Renling WanState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China.
Praveen Kumar KalavaguntaState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China.
Li LiuState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China.
Wenting LvState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China.
Tong QiaoVascular Surgery Department, Nanjing Drum Tower Hospital, Nanjing, 210008, China.
Jing ShangState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China. shangjing21cn@163.com.
Huali WuState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China. wu5254307@163.com.
China Pharmaceutical University · CNNanjing Drum Tower Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent literature reported the adverse effects of high-fat diet (HFD) on animal's emotional and cognitive function. An HFD-induced obesity/hyperlipidemia is accompanied by hormonal and neurochemical changes that can lead to depression. The important roles of gut-derived serotonin (5-Hydroxytryptamine, 5-HT) during this processing have been increasingly focused. Hence, to determine the potential role of gut-derived serotonin, HFD model was established in C57BL/6 mice. At the 4th week of feeding, a pharmacologic inhibitor of gut-derived 5-HT synthesis LP533401 (12.5 mg/kg/day), simvastatin (SIM) (5 mg/kg/day) and benzafibrate (BZ) (75 mg/kg/day) were administered for two weeks by oral gavage. Then, intraperitoneal glucose tolerance test (IPGTT), open field test (OFT), tail suspension test (TST), forced swim test (FST), sucrose preference test (SPT) were used to evaluate metabolic and neurobehavioral performances. Immunohistochemical staining, real-time quantitative PCR and other methods were to explore possible mechanisms. It was found that HFD feeding and drug treatments had some significant effects on neurobehaviors and brain: (1) All administrations reduced the total cholesterol (TC) and triglyceride (TG) parametric abnormality caused by HFD. LP533401 and SIM could significantly improve the impaired glucose tolerance, while BZ had no significant effect. (2) LP533401, SIM and BZ alleviated depression-like behavior of HFD mice in OFT, TST, FST and SPT. (3) LP533401 and SIM reversed the inhibition of Tryptophan Hydroxylase 2, Tph2 gene expression and the activation of Indoleamine 2,3-dioxy-Genase, IDO expression in HFD-treated brain, whereas BZ did not. (4) LP533401, SIM and BZ restored the inhibitory expression of 5-HT

Indexed as

Diet, High-FatAnimalsBehavior, AnimalBrainDepressionExploratory BehaviorMaleMetabolic DiseasesMice, Inbred C57BLObesitySerotoninSerotoninBehavioral changesGlucose intoleranceHigh-fat diet (HFD)Hippocampal 5-HT1A receptorsObesityPeripheral 5-HT

Identifiers

PMID30931486
OpenAlexW2933268374

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.